Cobenfy (xanomeline-trospium chloride) for schizophrenia: A clinical update. (PubMed, Australas Psychiatry) - Sep 16, 2026 - "As of March 2026, no Therapeutic Goods Administration (TGA) registration application has been submitted. However, Australian doctors working in psychiatry should familiarise themselves with the evidence base and anticipated prescribing challenges in advance of TGA review."
Journal • CNS Disorders • Psychiatry • Schizophrenia
|